WallStSmart
ACRV

Acrivon Therapeutics, Inc. Common Stock

NASDAQ: ACRV · HEALTHCARE · BIOTECHNOLOGY

$1.91
-7.74% today

Updated 2026-06-05

Market cap
$66.77M
P/E ratio
P/S ratio
EPS (TTM)
$-2.00
Dividend yield
52W range
$1 – $4
Volume
0.7M

Acrivon Therapeutics, Inc. Common Stock (ACRV) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item202020212022202320242025
Operating cash flow$-2.80M$-13.98M$-30.12M$-42.64M$-65.67M$-63.66M
Capital expenditures$15000.00$238000.00$2.17M$1.29M$2.77M$1.67M
Depreciation
Stock-based comp$3000.00$497000.00$2.19M$11.62M$14.29M$14.72M
Free cash flow$-2.82M$-14.22M$-32.28M$-43.93M$-68.44M$-65.33M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$-70.08M

Frequently asked questions

How much free cash flow does ACRV generate?

ACRV produced $-65.33M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACRV's balance sheet healthy?

ACRV holds $41.50M in cash and equivalents against — in long-term debt, on $112.52M of shareholder equity. That debt is best read against the cash flow the business throws off each year.